Trial reportActa orthopaedica2025
Generalizability of the Progressive Resistance Training versus Total Hip Arthroplasty (PROHIP) trial: a cross-sectional study of 402 patients in Denmark.
Trial report in Acta orthopaedica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background and purposeThere is ongoing debate over whether results from randomized trials assigning patients to surgery or first-line treatment can be generalized to clinical practice. Therefore, we aimed to compare patients with hip osteoarthritis accepting enrollment in the Progressive Resistance Training versus Total Hip Arthroplasty (PROHIP) trial in Denmark with those declining (enrolled in an observational cohort [non-PROHIP]).
methodsWe used a cross-sectional study design to compare demographics and patient-reported outcomes among patients eligible for enrollment in the PROHIP trial. We used the standardized difference (StdDiff), the absolute difference with 95% confidence interval (CI), and the propensity (odds ratio [OR]) of accepting participation in the PROHIP trial to assess imbalances between groups. We pre-specified that StdDiff values < 0.2 indicated a negligible difference, whereas values ≥ 0.8 indicated incomparability.
results402 patients were included, with 109 in the PROHIP trial and 293 in the non-PROHIP cohort. Patients enrolled in the PROHIP trial had a mean (standard deviation [SD]) Oxford Hip Score at baseline of 25.1 (SD 5.9) compared with 22.6 (SD 6.9) in the non-PROHIP cohort (between-group difference, 2.5 points [CI 1.1-4.0], StdDiff 0.4, OR 1.06 [CI 1.02-1.10]). This pattern was consistent across almost all secondary patient-reported outcomes applied in the PROHIP trial. For most demographic variables, there were negligible between-group differences at baseline.
conclusionWe found minimal imbalances in some baseline demographic variables and most patient-reported outcomes, with those who accepted enrollment in the PROHIP trial having more favorable outcomes at recruitment than those who declined. However, most differences were not clinically important.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.